VTE risk in hormone therapy: Lower with transdermal estradiol than with oral estrogen, study finds

Experience from research and practice have demonstrated that venous thromboembolism (VTE) is a common complication of hormone therapy. Now, that obstacle to safe treatment of the symptoms of menopause may be tempered by the results of a large population-based study, suggesting that patients who take transdermal estradiol have a 30% lower incidence of VTE than those who take oral estrogen only. The lower risk of VTE was also statistically significant when transdermal estradiol was at high dose.^1,2

Study results were presented at the 22nd Annual Meeting of the North American Menopause Society (NAMS) in Washington, DC, in September.

In the retrospective, matched-cohort study that compared high-dose transdermal estradiol and oral estrogen-only HT agents, 115 of 27,018 users of the estradiol transdermal system (ETS) and 164 of 27,018 users of the oral estrogen developed VTE. In those taking high-dose ETS (0.1 mg/day), 32 of 8,956 ETS users and 65 of 8,956 oral users of high dose oral estrogen developed VTE.^1,2

“The incidence of hospitalization related to VTE events among the ETS users was also significantly lower, relative to the oral-only hormone therapy users,” said Eric Beresford, PharmD, presenter and coauthor of the study and director of medical affairs at Forest Research Institute, Secaucus, NJ, who previously worked at Novartis.¹

2011-2012 NAMS President JoAnn Manson, MD, DrPH, HCMP, commented that the study “provides further reassurance that transdermal estrogen may not increase the risk of venous thrombosis.”¹

“We do know that transdermal products don’t go directly to the liver and don’t increase the production of clotting proteins to the same extent as the oral estrogen products,” Manson added, “so it’s biologically very plausible. I do think that it’s a reasonable choice for trying to avoid venous thrombosis risk.”¹

For details: www.medscape.com/viewarticle/750558.

We want to hear from you! Tell us what you think.

Experience from research and practice have demonstrated that venous thromboembolism (VTE) is a common complication of hormone therapy. Now, that obstacle to safe treatment of the symptoms of menopause may be tempered by the results of a large population-based study, suggesting that patients who take transdermal estradiol have a 30% lower incidence of VTE than those who take oral estrogen only. The lower risk of VTE was also statistically significant when transdermal estradiol was at high dose.^1,2

Study results were presented at the 22nd Annual Meeting of the North American Menopause Society (NAMS) in Washington, DC, in September.

In the retrospective, matched-cohort study that compared high-dose transdermal estradiol and oral estrogen-only HT agents, 115 of 27,018 users of the estradiol transdermal system (ETS) and 164 of 27,018 users of the oral estrogen developed VTE. In those taking high-dose ETS (0.1 mg/day), 32 of 8,956 ETS users and 65 of 8,956 oral users of high dose oral estrogen developed VTE.^1,2

“The incidence of hospitalization related to VTE events among the ETS users was also significantly lower, relative to the oral-only hormone therapy users,” said Eric Beresford, PharmD, presenter and coauthor of the study and director of medical affairs at Forest Research Institute, Secaucus, NJ, who previously worked at Novartis.¹

2011-2012 NAMS President JoAnn Manson, MD, DrPH, HCMP, commented that the study “provides further reassurance that transdermal estrogen may not increase the risk of venous thrombosis.”¹

“We do know that transdermal products don’t go directly to the liver and don’t increase the production of clotting proteins to the same extent as the oral estrogen products,” Manson added, “so it’s biologically very plausible. I do think that it’s a reasonable choice for trying to avoid venous thrombosis risk.”¹

For details: www.medscape.com/viewarticle/750558.

We want to hear from you! Tell us what you think.

Experience from research and practice have demonstrated that venous thromboembolism (VTE) is a common complication of hormone therapy. Now, that obstacle to safe treatment of the symptoms of menopause may be tempered by the results of a large population-based study, suggesting that patients who take transdermal estradiol have a 30% lower incidence of VTE than those who take oral estrogen only. The lower risk of VTE was also statistically significant when transdermal estradiol was at high dose.^1,2

Study results were presented at the 22nd Annual Meeting of the North American Menopause Society (NAMS) in Washington, DC, in September.

In the retrospective, matched-cohort study that compared high-dose transdermal estradiol and oral estrogen-only HT agents, 115 of 27,018 users of the estradiol transdermal system (ETS) and 164 of 27,018 users of the oral estrogen developed VTE. In those taking high-dose ETS (0.1 mg/day), 32 of 8,956 ETS users and 65 of 8,956 oral users of high dose oral estrogen developed VTE.^1,2

“The incidence of hospitalization related to VTE events among the ETS users was also significantly lower, relative to the oral-only hormone therapy users,” said Eric Beresford, PharmD, presenter and coauthor of the study and director of medical affairs at Forest Research Institute, Secaucus, NJ, who previously worked at Novartis.¹

2011-2012 NAMS President JoAnn Manson, MD, DrPH, HCMP, commented that the study “provides further reassurance that transdermal estrogen may not increase the risk of venous thrombosis.”¹

“We do know that transdermal products don’t go directly to the liver and don’t increase the production of clotting proteins to the same extent as the oral estrogen products,” Manson added, “so it’s biologically very plausible. I do think that it’s a reasonable choice for trying to avoid venous thrombosis risk.”¹

For details: www.medscape.com/viewarticle/750558.

We want to hear from you! Tell us what you think.